High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo
Abstract Background Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high. The molecular mechanism of this resistance has n...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2017-12-01
|
| coleção: | BMC Cancer |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s12885-017-3868-2 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|